Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Cash Flow (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Net Cash Flow for 16 consecutive years, with $74.7 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 22743.43% to $74.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.2 million through Dec 2025, up 3670.75% year-over-year, with the annual reading at $127.2 million for FY2025, 3670.75% up from the prior year.
  • Net Cash Flow hit $74.7 million in Q4 2025 for Ironwood Pharmaceuticals, up from $47.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $84.1 million in Q1 2023 to a low of -$565.5 million in Q2 2023.
  • Historically, Net Cash Flow has averaged -$7.4 million across 5 years, with a median of $24.6 million in 2024.
  • Biggest five-year swings in Net Cash Flow: plummeted 535.3% in 2023 and later skyrocketed 22743.43% in 2025.
  • Year by year, Net Cash Flow stood at $45.9 million in 2021, then soared by 78.87% to $82.0 million in 2022, then tumbled by 123.48% to -$19.3 million in 2023, then skyrocketed by 101.7% to $327000.0 in 2024, then surged by 22743.43% to $74.7 million in 2025.
  • Business Quant data shows Net Cash Flow for IRWD at $74.7 million in Q4 2025, $47.6 million in Q3 2025, and -$15.0 million in Q2 2025.